secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102389
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete
--------------------------------------------------------------------------------

- Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.
- Cash, cash equivalents and marketable securities $1.2B as of June 30, 2025; runway into 2028.
- BEAM-302 Phase 1/2: 17 patients dosed; expanded dose exploration underway; Part B enrollment initiated; data expected early 2026.
- BEAM-101 BEACON trial: 30 SCD patients dosed (adults + first adolescent); updated data expected by end of 2025.
- FDA granted orphan drug designation for BEAM-101 and BEAM-302, and RMAT designation for BEAM-302.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025102389/0000950170-25-102389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025102389/beam-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer